Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jeffrey Ives Insider Profile
4 Followers
Jeffrey Ives, Director at Cara Therapeutics, holds 0.00 shares in Acumen Pharmaceuticals (Ticker: ABOS), holds 47.84K shares in Cara Therapeutics (Ticker: CARA).
Jeffrey Ives has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jeffrey Ives holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jeffrey Ives
Jeffrey Ives's Trading History
Cara Therapeutics
Jun 05, 2023
Director
Uninformative Buy
―
$34.20K
Acumen Pharmaceuticals
Aug 18, 2023
Director
Uninformative Sell
272.33K
$0.00
List of latest transactions for each holding click on a transaction to see Jeffrey Ives's performance on stock
You May Also Like
Jeffrey Ives insider profile FAQ
What is the percentage of profitable transactions made by Jeffrey Ives?
The percentage of profitable transactions made by Jeffrey Ives is ―.
What is the average return per transaction made by Jeffrey Ives?
The average return per transaction made by Jeffrey Ives is ―.
What stocks does Jeffrey Ives hold?
Jeffrey Ives holds: CARA, ABOS stocks.
What was Jeffrey Ives’s latest transaction?
Jeffrey Ives latest transaction was an Uninformative Sell of $272.33K.
What was Jeffrey Ives's most profitable transaction?
Jeffrey Ives’s most profitable transaction was an Informative Sell of CARA stock on November 16, 2021. The return on the trade was 27.00%.
What is Jeffrey Ives's role in Cara Therapeutics?
Jeffrey Ives's role in Cara Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.